| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
2E,6E-farnesol
2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
Cross Reference
Introduction
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2E,6E-farnesol?
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
PubChem Associated disorders and diseases
What pathways are associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2E,6E-farnesol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2E,6E-farnesol?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 2E,6E-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hogan DA | Talking to themselves: autoregulation and quorum sensing in fungi. | 2006 | Eukaryotic Cell | pmid:16607008 |
| Piispanen AE et al. | Roles of Ras1 membrane localization during Candida albicans hyphal growth and farnesol response. | 2011 | Eukaryotic Cell | pmid:21908593 |
| Kloog Y et al. | Ras chaperones: new targets for cancer and immunotherapy. | 2013 | Enzymes | pmid:25033809 |
| Menn JJ and Pallow FM | Development of morphogenetic agents in insect control. | 1975 | Environ Lett | pmid:1091483 |
| Bellahcène A et al. | Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. | 2007 Mar-Apr | Endothelium | pmid:17497369 |
| Leitner JW et al. | Hyperinsulinemia potentiates activation of p21Ras by growth factors. | 1997 | Endocrinology | pmid:9112423 |
| Bhavnani BR and Woolever CA | Formation of steroids by the pregnant mare. VI. Metabolism of [14C]farnesyl pyrophosphate and [3H]dehydroepiandrosterone injected into the fetus. | 1978 | Endocrinology | pmid:155006 |
| Berstein LM et al. | New approaches to the understanding of tamoxifen action and resistance. | 2003 | Endocr. Relat. Cancer | pmid:12790788 |
| Ohguro H et al. | Carboxyl methylation and farnesylation of transducin gamma-subunit synergistically enhance its coupling with metarhodopsin II. | 1991 | EMBO J. | pmid:1935895 |
| Shearer AG and Hampton RY | Lipid-mediated, reversible misfolding of a sterol-sensing domain protein. | 2005 | EMBO J. | pmid:15635451 |
| Gefarnate. | 1968 | Drug Ther Bull | pmid:5722353 | |
| Egorov IA et al. | [Farnesol in brandy]. | 1967 Mar-Apr | Dokl. Akad. Nauk SSSR | pmid:5623628 |
| Neeman R et al. | Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. | 2014 | Dig. Dis. Sci. | pmid:24942325 |
| Oron T et al. | Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid. | 2012 | Dig. Dis. Sci. | pmid:21901261 |
| Zvibel I et al. | The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. | 2008 | Dig. Dis. Sci. | pmid:17934818 |
| Thorpe JL et al. | Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation. | 2004 | Dev. Cell | pmid:14960282 |
| Scheman A et al. | European Directive fragrances in natural products. | 2014 Mar-Apr | Dermatitis | pmid:24603515 |
| Décanis N et al. | Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human beta-defensin 2 production. | 2009 | Cytokine | pmid:19121950 |
| Gilpin S and Maibach H | Allergic contact dermatitis caused by farnesol: clinical relevance. | 2010 | Cutan Ocul Toxicol | pmid:20858058 |
| Hogan DA and Muhlschlegel FA | Candida albicans developmental regulation: adenylyl cyclase as a coincidence detector of parallel signals. | 2011 | Curr. Opin. Microbiol. | pmid:22014725 |
| Fuchs BB and Mylonakis E | Using non-mammalian hosts to study fungal virulence and host defense. | 2006 | Curr. Opin. Microbiol. | pmid:16814595 |
| Hampton RY | Genetic analysis of hydroxymethylglutaryl-coenzyme A reductase regulated degradation. | 1998 | Curr. Opin. Lipidol. | pmid:9559264 |
| Fayard E et al. | Xol INXS: role of the liver X and the farnesol X receptors. | 2001 | Curr. Opin. Lipidol. | pmid:11264982 |
| Gomes FI et al. | Effect of farnesol on planktonic and biofilm cells of Staphylococcus epidermidis. | 2009 | Curr. Microbiol. | pmid:19365686 |
| Gomes F et al. | Effect of farnesol on structure and composition of Staphylococcus epidermidis biofilm matrix. | 2011 | Curr. Microbiol. | pmid:21800262 |
| Mor A et al. | Immunomodulatory properties of farnesoids: the new steroids? | 2013 | Curr. Med. Chem. | pmid:23432580 |
| Goossens A and Merckx L | Allergic contact dermatitis from farnesol in a deodorant. | 1997 | Contact Derm. | pmid:9385513 |
| Frosch PJ et al. | Patch testing with a new fragrance mix detects additional patients sensitive to perfumes and missed by the current fragrance mix. | 2005 | Contact Derm. | pmid:15859993 |
| Frosch PJ et al. | Patch testing with a new fragrance mix - reactivity to the individual constituents and chemical detection in relevant cosmetic products. | 2005 | Contact Derm. | pmid:15859994 |
| Hemmer W et al. | Axillary dermatitis from farnesol in a deodorant. | 2000 | Contact Derm. | pmid:10727172 |
| Schnuch A et al. | Contact allergy to farnesol in 2021 consecutively patch tested patients. Results of the IVDK. | 2004 | Contact Derm. | pmid:15153123 |
| Patrassi G | [The relationship between collagenosis and rheumatic disease]. | 1966 | Concours Med | pmid:5904237 |
| Fioravanti CF and MacInnis AJ | The identification and characterization of a prenoid constituent (farnesol) of Hymenolepis diminuta (Cestoda). | 1977 | Comp. Biochem. Physiol., B | pmid:299634 |
| Abbasnezhad H et al. | Two different mechanisms for adhesion of Gram-negative bacterium, Pseudomonas fluorescens LP6a, to an oil-water interface. | 2008 | Colloids Surf B Biointerfaces | pmid:17997081 |
| da Silva Morais A et al. | Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. | 2008 | Clin. Sci. | pmid:17678500 |
| Aizman E et al. | Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines. | 2014 | Clin. Exp. Immunol. | pmid:24215151 |
| Katzav A et al. | Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). | 2001 | Clin. Exp. Immunol. | pmid:11737078 |
| Gana-Weisz M et al. | The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. | 2002 | Clin. Cancer Res. | pmid:11839677 |
| Bachireddy P et al. | Getting at MYC through RAS. | 2005 | Clin. Cancer Res. | pmid:15958607 |
| Yaari S et al. | Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. | 2005 | Clin. Cancer Res. | pmid:15958613 |
| Barkan B et al. | The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. | 2006 | Clin. Cancer Res. | pmid:17000690 |
| Buffatti G | [Geranyl farnesyl acetate in the treatment of gastroenteritis in the infant]. | 1965 | Clin Pediatr (Bologna) | pmid:5882341 |
| Badar T et al. | Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. | 2015 | Clin Lymphoma Myeloma Leuk | pmid:25795639 |
| George J et al. | Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. | 2002 | Circulation | pmid:12021230 |
| Luxová A et al. | Absolute configuration of chiral terpenes in marking pheromones of bumblebees and cuckoo bumblebees. | 2004 | Chirality | pmid:15034905 |
| Akiyama H et al. | Actions of farnesol and xylitol against Staphylococcus aureus. | 2002 | Chemotherapy | pmid:12138327 |
| Raptis C et al. | Acid-catalyzed cyclization of terpenes under homogeneous and heterogeneous conditions as probed through stereoisotopic studies: a concerted process with competing preorganized chair and boat transition states. | 2009 | Chemistry | pmid:19780112 |
| Ludolph B et al. | Solution- and solid-phase synthesis of the polybasic lipid-modified C termini of Rho A and K-Ras 4B. | 2002 | Chembiochem | pmid:12210992 |
| Bondar OP et al. | Effects of farnesol on the thermotropic behavior of dimyristoylphosphatidylcholine. | 1994 | Chem. Phys. Lipids | pmid:7820904 |
| Qamar W and Sultana S | Farnesol ameliorates massive inflammation, oxidative stress and lung injury induced by intratracheal instillation of cigarette smoke extract in rats: an initial step in lung chemoprevention. | 2008 | Chem. Biol. Interact. | pmid:18793622 |